Prerpints.org logo
Preprint
Article

Preparation and Evaluation of Niosomal Formulation for Solubility Enhancement of Anti-fungal Agent for the Treatment of Oral Candidiasis

Altmetrics

Downloads

226

Views

119

Comments

0

This version is not peer-reviewed

Submitted:

09 April 2024

Posted:

11 April 2024

You are already at the latest version

Alerts
Abstract
Human fungal pathogen Candida albicans causes oral infectious diseases such as oral thrush in immunocompromised patients with hyposalivation, diabetes mellitus, prolonged use of anti-biotics or immunosuppressive medicines and poor oral hygiene. An anti-fungal medication classified as a BCS class II drug, Clotrimazole has high permeability and low solubility in water. It is commercially available as lozenges, which do not uniformly distribute the drug within saliva for local therapy. This results in higher dose frequency and lower patient compliance. Therefore, in this study we proposed a niosomal based subgingival film formulation of clotrimazole for enhancing drug efficacy by improving drug solubilization capacity and improving patient compliance by prolonging the release of drug at the targeted site and reducing the dose frequency to show effective anti-fungal activity. The prepared niosomal film showed good entrapment efficiency and anti-fungal activity. Niosomal film showed better release pattern than drug loaded film.
Keywords: 
Subject: Medicine and Pharmacology  -   Pharmacy

1. Introduction

Oral health is an important aspect of an individual’s overall health status. Teeth and their supporting (periodontal) structures are of main importance to oral health. Candida albicans, a human fungal pathogen causes oral infectious diseases such as oral thrush which affect the tongue and supporting structures of the teeth such as gums [1]. Presence of C. albicans does not cause any harm as the beneficial bacteria controls the overgrowth of the C. albicans in the oral cavity. The risk of oral thrush increases in immunocompromised patients with hyposalivation, diabetes mellitus, prolonged use of anti-biotics or immunosuppressive medicines and poor oral hygiene. The white patches appearing as discrete lesions on the buccal mucosa, throat, tongue and gum linings that develop into confluent pseudo membranes resembling milk curds can be life-threatening as it may enter the bloodstream and affect the other organs and cause septic shock [2]. To treat oral thrush various formulations like gels, lozenges, creams, mouth rinses, and suspensions are used to deliver the drug locally into the oral cavity.
Administration of drug with less residence time or less solubilization capacity of drug decreases the efficiency of medication to treat oral thrush. So, local periodontal therapy was applied where anti-fungal agents can be directly administered to the periodontal pocket and thus inhibits the growth of human fungal pathogen. Subgingival film is a local sustained release delivery system for the delivery of an anti-microbial agent to achieve and maintain the therapeutic levels of the drug for the required period of time. This intrapocket delivery device is a dosage form that has several advantageous physical properties for intrapocket use. The dimensions and shape of the film can be easily controlled to correspond to the dimensions of the periodontal pocket to be treated. It is easily and rapidly inserted and remain submerged into the periodontal pocket with minimal discomfort to the patient while eating or practising oral hygiene habits.
Clotrimazole is a broad-spectrum antimycotic drug that is commonly used to treat Candida albicans and other fungal infections. Clotrimazole inhibits the biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, causing damage and altering the permeability of the cell membrane. This causes leakage and loss of essential intracellular compounds, ultimately leading to cell lysis. It is typically given as lozenges. Clotrimazole is a BCS Class II Drug. It shows low solubility and high permeability.
Niosomes are the best carriers to design the novel drug delivery system for poorly soluble drugs. Niosomes are self-assembled microscopic lamellar vesicles of size range between 20 nm to 50 µm formed on admixture of non-ionic surfactant and cholesterol with subsequent hydration in aqueous media and are capable of entrapping both hydrophobic and hydrophilic drug molecules [1]. Therefore, in this study we proposed a niosomal based subgingival film formulation of clotrimazole for enhancing drug efficacy by improving drug solubilization capacity and improving patient compliance by prolonging the release of drug at the targeted site and reducing the dose frequency to show effective anti-fungal activity.

2. Materials and Methods

2.1. Materials

Clotrimazole was procure as a gift sample from Cipla Ltd, Mumbai, India. Sorbitan Monostearate (span 60), Cholesterol, Polyethylene Glycol 400 (PEG 400), Chloroform and Methanol was purchased from Molychem, Mumbai, India. Polyvinyl alcohol was purchased from West Coast Laboratories, Mumbai, India and Dialysis Membrane-60 was acquired from HiMedia Laboratories Pvt., Ltd., Mumbai, India. The reagents and solvents used were all of analytical grade.

2.2. Optimization of Niosomes Encapsulated ClotrimazolE by Experimental Design

The Plackett Burman Factorial design was employed in this study for screening of the significant factors as shown in Table 1. Based on the results obtained from Plackett Burman design, a 23 Full Factorial design was employed to study the effect of independent variables i.e., speed of rotation, temperature and amount of solvent on dependent variable i.e., percentage entrapment efficiency. Design Expert software version 13, Stat Ease Inc., USA was used to correlate dependent and independent variables using the following polynomial equation:
Y = A0 + A1X1 + A2X2 + A3X3 + A12X1X2 + A13X1X3 + A23X2X3 + A123X2X3
where, Y is the response, A0 the constant and A1 to A3 are the coefficients of the response values

2.3. Preparation of Niosomes Encapsulated Clotrimazole

Thin film Hydration method was employed to prepare niosomes. An optimized ratio 1:1:2.5 of drug, cholesterol and surfactant were dissolved in 10 ml of chloroform with continuous stirring. Then solvent was evaporated using rotatory evaporator (Trident Labortek) at 42. 9ᵒC for 1 hour at 109 rpm. A thin film formed on the inner periphery of the round bottom flask was hydrated using 15.8 ml pH 6.8 phosphate buffer saline solution using rotary evaporator for 45 mins at 42.9ᵒC. The prepared niosomes were kept overnight in refrigerator (4ᵒC). The niosomal suspension was sonicated for 20 mins and were centrifuged at a speed of 10,000 rpm for 30 min using cooling centrifuge to separate out the supernatant and sediment.

2.4. Preparation of Niosomal Based SubgingivaL Film

The required amount of polyvinyl alcohol was dissolved in water by heating it on water bath with continuous stirring. This polymeric solution was kept on magnetic stirrer (Remi 2MLH) to avoid air entrapment. Then required amount of prepared niosomes and PEG 400 was added to this polymeric solution with continuous stirring and then it was poured at the center of the levelled rectangular glass slab and allowed to dry at room temperature.

2.5. Characterization of Niosomal Based Subgingival FiLm

2.5.1. Solubility Studies

The solubility study was studied by adding 1 gram of drug in different solvents like chloroform, methanol, ethanol, phosphate buffer pH 6.8, water and shaken on cyclomixer (Eltek VM 301) at room temperature and solubility of drug in solvent was recorded.

2.5.2. Scanning Electron Microscopy (SEM)

The morphology of drug was examined by SEM. Small amount of drug was mounted on the SEM sample stab using a double-sided sticking tape. The samples are coated with gold (200 Aᵒ) under reduced pressure (65 Pascal) for 2 min using an ion sputtering device. The gold-coated samples were observed under the SEM and photomicrographs of suitable magnifications were obtained by using Quanta 200 ESEM at Icon labs Pvt. Ltd., Sanpada, Navi Mumbai.

2.5.3. Spectral Characterization of drug by UV Spectroscopy

2.5.3. (a) Determination of Maximum Wavelength

Standard stock solution of 500 µg/ml was prepared by dissolving 50 mg of drug in 100 ml of methanol and diluted with methanol and phosphate buffer pH 6.8 to get respective UV spectra in the range of 200-400 nm using methanol and phosphate buffer pH 6.8 as blank. The absorbance maxima for the drug were determined using UV visible spectrophotometer 1800, Shimadzu.

2.5.3. (b) Calibration Curve of Drug

Standard stock solution of 500 µg/ml was used to prepare different dilutions with methanol and phosphate buffer pH 6.8 in concentration range of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500 µg/ml. The absorbance of these solutions was measured at 263 nm using methanol and phosphate buffer pH 6.8 as blank solution. The absorbance values were plotted against concentration to obtain standard graph.

2.5.4. Fourier Transform-Infrared Spectroscopy (FTIR)

The dry sample of drug and excipients in powdered form was analyzed for interference of excipients with the drug using potassium bromide pellet method. The prepared sample was scanned using Shimadzu IR Spirit.

2.5.5. Differential Scanning Calorimeter (DSC)

The thermal analysis of pure drug and formulation was performed by keeping 1.5 mg of sample on aluminium pan at 10 to 350ᵒC at a heating rate of 0.5ᵒC/min using TA DSC 25 at SVKM’s Shri C. B. Patel Research Centre, Vile Parle (W), Mumbai.

2.5.6. Percent Drug Entrapment Efficiency (%EE)

Entrapment Efficiency of drug loaded niosomes was carried out by ultrafiltration method. The drug loaded niosomal suspension were centrifuged at a speed of 10000 rpm for 30 min using cooling centrifuge (Eltek Refrigerated Centrifuge RC 4010 F) and the sediment was assayed for entrapped drug concentration by diluting it with phosphate buffer pH 6.8 and determining the absorbance at 263 nm using UV spectrophotometer. The percent drug entrapment efficiency (%EE) was calculated using following formula:
E n t r a p m e n t   E f f i c i e n c y   % = E n t r a p p e d   D r u g T o t a l   a m o u n t   o f   d r u g   × 100

2.5.7. Particle Size, Polydispersity Index and Zeta Potential

The prepared niosomes was taken in small amount and diluted with 10 ml of double distilled water. This prepared sample was then sonicated for 20 min and placed in sample holder and scanned using HORIBA SZ-100 Nanoparticle Analyzer for determination of mean particle size, polydispersity index and zeta potential.

2.5.8. Transmission Electron Microscopy (TEM)

The characterization of vesicles was carried out by placing small amount of drug loaded niosomes on the carbon film covered copper grid and obtaining photomicrographs of suitable magnifications using FEI Tecnai 12 Transmission Electron Microscopes at Icon labs Pvt. Ltd., Sanpada, Navi Mumbai.

2.5.9. Antifungal Activity

A placebo subgingival film, drug loaded subgingival film and drug loaded niosomes based subgingival film was prepared and cut into 1×1 cm. These films were exposed to a fungi species, Candida albicans and incubated at 20-25ᵒC for 2-5 days using disk diffusion method. These studies were carried out at Micro Bio Laboratory, Thane, Mumbai.

2.5.10. Drug Content

Drug loaded niosome based subgingival film was cut into 1×1 cm and dissolved in methanol and diluted upto 10 ml with pH 6.8 phosphate buffer solution. The absorbance of the solution was recorded at 263 nm using UV spectrophotometer by keeping pH 6.8 phosphate buffer solution as blank. The percent drug content was calculated by using following formula:
D r u g   C o n t e n t   % = A m o u n t   o f   d r u g   i n   t h e   f o r m u l a t i o n T o t a l   a m o u n t   o f   d r u g   × 100

2.5.11. Percent Moisture Uptake

Drug loaded films were weighed individually and then it was kept in a desicator containing potassium chloride to maintain 84% RH for 24 hours. Then films were reweighed and percent moisture uptake was calculated using the following formula:
M o i s t u r e   U p t a k e   % = F i n a l   W e i g h t − I n i t i a l   W e i g h t I n i t i a l   W e i g h t   × 100

2.5.12. Percent Moisture Content

Drug loaded films were weighed individually and then it was kept in a desicator containing calcium chloride at room temperature for 24 hours. After 24 hours it was taken out and reweighed and percent moisture content was calculated using the formula:
M o i s t u r e   C o n t e n t   % = I n i t i a l   W e i g h t − F i n a l   W e i g h t F i n a l   W e i g h t   × 100

2.5.13. Thickness Measurement

The niosomes based subgingival film were cut into 1×1 cm and thickness were determined by digital vernier caliper.

2.5.14. Weight Determination

The niosomes based subgingival film were cut into 1×1 cm and all the 20 films were measured individually on an electronic balance and average weight was calculated.

2.5.15. Tensile Strength

Tensile strength of the niosomes based subgingival film were determined with tensile strength tester by fixing the film between two load cell grips of the tester. When the force is gradually applied the upper movable load cell grip pulls the film till it breaks and shows the reading on the tester dial.

2.5.16. Folding Endurance

Folding endurance is determined by repeatedly folding the film till it breaks.

2.5.17. In-Vitro Diffusion and Drug Release

The in-vitro diffusion study was carried out using Franz Diffusion Cell. The receptor compartment was filled with 20 ml of Phosphate buffer pH 6.8 and sample was kept in donor compartment over a dialysis membrane that was soaked in phosphate buffer pH 6.8 solution for 24 hours. This assembly was kept on the magnetic stirrer at 50 rpm speed at room temperature. 2 ml of aliquot was withdrawn from the receptor compartment at the time interval of 1, 2, 3, 4, 5, 6, 24, 48, 72, 96, 120, 144, 168, 192 hours and 2 ml of medium i.e., phosphate buffer pH 6.8 was added back to the receptor compartment at the mentioned time interval and analyzed using UV spectrophotometer at 263 nm wavelength. Then percent cumulative drug release was determined and in-vitro drug release was studied using different release kinetic profiles.

2.5.18. Stability Studies

The stability of the optimized formulation was determined by wrapping the subgingival film in aluminium foil and storing the formulation at 5-8ᵒC and 25ᵒC for upto 3 months as per ICH guidelines and analyzing the stability by evaluating the appearance, percent entrapment efficiency and percent drug content.

3. Results and Discussions

3.1. Optimization of Niosomes

In this study, we employed Plackett Burman Factorial Design for screening of the significant factors which is depicted in Table 2. Based on these results 3 factors 2 level full factorial design was used to study the effect of independent variables i.e., speed of rotation, cholesterol: surfactant ratio, hydration time, temperature, amount of hydration solvent on dependent variable i.e., percent entrapment efficiency. The results of factorial design are depicted in Table 3. Based on these studies it was observed that when most significant factor i.e., temperature and speed of rotation increases the entrapment efficiency decreases as depicted in Figure 1. ANOVA statistical analysis study suggest that the selected model is significant for the responses as shown in Table 4. The model F-value of 53.57 implies the model is significant. There is only a 1.84% chance that an F-value this large could occur due to noise. p-values less than 0.05 indicate model terms are significant. In this case B, C, AB, ABC are significant model terms. Values greater than 0.1 indicate the model terms are not significant. If there are many insignificant model terms, model reduction may improve your model. The results of regression analysis suggest that the predicted R2 of 0.8814 is in reasonable agreement with the adjusted R2 of 0.9741; i.e., the difference is less than 0.2 (Table 5). The observed response was as per the predicted response which is indicating the validity of the optimization design (Table 6). So, the optimized formulation was prepared and used for further experiments.
The polynomial equation obtained from this study to correlate the independent and dependent variable was depicted as follow:
Y = 76.83 − 0.8475 A − 1.44 B − 2.96 C − 1.39 A B − 3.23 A B C

3.2. Characterization of Niosomal Based Subgingival Film

3.2.1. Solubility Studies

The solubility of clotrimazole was observed in chloroform and methanol, slight solubility in phosphate buffer pH 6.8, insolubility in water and it was sparingly soluble in ethanol. So, analytical grade of chloroform and methanol was used as a solvent for this experimental study.

3.2.2. Scanning Electron Microscopy (SEM)

The morphology of clotrimazole was examined by SEM analysis. As per Figure 2, the pure form of drug was in crystal form.

3.2.3. Spectral Characterization of Drug by UV Spectroscopy

The absorbance maxima for the clotrimazole were observed at 263 nm in both methanol and phosphate buffer pH 6.8 (Figure 3 and Figure 4). We observed a linear calibration curve for clotrimazole in both methanol and phosphate buffer pH 6.8 as depicted in Figure 5 and Figure 6 respectively.

3.2.4. Fourier Transform-Infrared Spectroscopy (FTIR)

The FTIR spectra of clotrimazole were compared with the FTIR spectra of physical mixture of drug and excipients. The comparative study showed that there was no significant shift in the positions of the wavenumbers, so there was no interaction between the drug and excipients (Table 7, Figure 7 and Figure 8).

3.2.5. Differential Scanning Calorimeter (DSC)

The thermal analysis of clotrimazole and formulation of drug loaded niosomes based subgingival film shows sharp endothermic peak at 144.1ᵒC and less intense endothermic peak at 83.28ᵒC. Based on this study we can conclude that drug was entrapped in niosomes and hence, solubility of the drug will increase (Figure 9).

3.2.6. Particle Size, Polydispersity Index and Zeta Potential

The observed particle size of optimized batch of niosomes was 2930.4 nm which lies within the range of 20 nm-50 µm. The polydispersity index was found to be 1.836 and zeta potential of optimized niosomes was found to be -68.2 mV which is depicted in Figure 10.

3.2.7. Transmission Electron Microscopy (TEM)

The morphology of prepared niosomes were studied through TEM analysis. Figure 11 illustrates the internal structure of drug loaded niosomes. The study validates that the prepared niosomes are spherical in shape with rigid boundaries.

3.2.8. Anti-FUNGAL Activity

The anti-fungal study illustrates that the clotrimazole loaded film and optimized clotrimazole loaded niosomal film shows anti-fungal activity but optimized clotrimazole loaded niosomal film shows better zone of inhibition against C. albicans than clotrimazole loaded film and no zone of inhibition was observed in placebo film sample and hence, we concluded that excipients does not show antifungal activity. The clotrimazole loaded film showed 32.68 mm zone of inhibition and optimized clotrimazole loaded niosomal film showed 36.07 mm zone of inhibition against C. albicans which is depicted in Figure 12.

3.2.9. In-Vitro Diffusion and Drug Release

A comparative study was performed between clotrimazole loaded film and clotrimazole loaded niosomal film for drug release profile. In-vitro diffusion study, as depicted in Figure 13 shows that 97% of drug was release in 192 hours from clotrimazole loaded film and 71% of drug was release in 192 hours from clotrimazole loaded niosomal film. Based on these drug release data various kinetic models was plotted to study the mechanism of drug release which is depicted in Figure 14 and Figure 15 and Table 8. The zero-order kinetic model for clotrimazole loaded niosomal film shows the regression coefficient near to one. So, based on this model a constant amount of drug was release from the film at per unit time.

3.2.10. Physico-Chemical Properties of Niosomal film

The prepared clotrimazole loaded niosomes based subgingival film was white in color with smooth appearance. This formulation was evaluated for various physico-chemical properties which is depicted in Table 9.

3.2.11. Stability Studies

The stability studies of the optimized formulation were carried out as per ICH guidelines at 5-8 ± 2ᵒC and 25 ± 2ᵒC for upto 3 months which is depicted in Table 10 and Figure 16.

4. Conclusion

As per the literature survey it was found that marketed preparation of niosomal subgingival film was not available for oral thrush. So, in this study, an optimized clotrimazole loaded niosomes were prepared using thin film hydration method and these niosomes were incorporated in a film by solvent casting method and evaluated for its physico-chemical properties. In-vitro characterization studies revealed that Clotrimazole can be incorporated in a slow-release device for the treatment of oral thrush. Niosomal subgingival film containing clotrimazole can be a promising alternative nano-carrier system for local drug delivery and enhanced anti-fungal activity against C. albicans.

Acknowledgments

The authors express their gratitude to Hyderabad Sindh National Collegiate Board and The Principal, Dr. Parag Gide of Dr. L. H. Hiranandani College of Pharmacy, Ulhasnagar for providing necessary support in due course of the work.

References

  1. Barot, T.; Rawtani, D.; Kulkarni, P. Development, characterization and in vitro–in vivo evaluation of Farnesol loaded niosomal gel for applications in oral candidiasis treatment. Heliyon 2021, 7, e07968. [Google Scholar] [CrossRef] [PubMed]
  2. Giorgi, A. Everything You Need to Know About Oral Thrush. Available online: https://www.healthline.com/health/thrush (accessed on 24 April 2019).
  3. Shirsand, S.B.; Kumar, G.R.; Keshavshetti, G.G.; Bushetti, S.S.; Swamy, P.V. Formulation and Evaluation of Clotrimazole Niosomal Gel for Tropical Application. RGUHS Journal of Pharmaceutical Sciences 2015, 5, 32–38. [Google Scholar] [CrossRef]
  4. Shwetha, K.; Bharath, S. Design of Chlorhexidine Loaded Periochip. SASTech- Technical Journal of RUAS 2015, 14, 37–39. [Google Scholar]
  5. Crowley, P.; Gallagher, H. Clotrimazole as a pharmaceutical: Past, present and future. J. Appl. Microbiol. 2014, 117, 611–617. [Google Scholar] [CrossRef] [PubMed]
  6. Kumar, Y.A.; Srinivas, S.; Hemanth, A.; Anitha, M. Preparation and Evaluation of Niosomes Containing Aceclofenac. Digest Journal of Nanomaterials and Biostructures 2010, 5, 249–254. [Google Scholar]
  7. Ruckmani, K.; Sankar, V. Formulation and Optimization of Zidovudine Niosomes. Aaps Pharmscitech 2010, 11, 1119–1127. [Google Scholar] [CrossRef] [PubMed]
  8. Sathyavathi, V.; Hasansathali, A.A.; Ilavarasan, R.; Sangeetha, T. Formulation and Evaluation of Niosomal in-situ Gel Ocular Delivery System of Brimonidine Tartarate. International Journal of Life Science and Pharma Research 2012, 2, 82–95. [Google Scholar]
  9. Sharma, S.K.; Chauhan, M.; Anilkumar, N. Span 60 Niosomal Oral Suspension of Fluconazole: Formulation and In-vitro Evaluation. Asian journal of pharmaceutical research and health care 2009, 1, 142–156. [Google Scholar]
  10. Zarei, M.; Norouzian, D.; Chiani, M.; Ebrahimi, H.; Mohammadi, M.; Akbarzadeh, A. Advantages of Paclitaxel-Loaded Nano Niosomes to Nanoliposomal Formulation: An In-vitro Study. International Journal of Life Sciences Biotechnology and Pharma Research 2013, 2, 335–342. [Google Scholar]
  11. Jadon, P.S.; Gajbhiye, V.; Jadon, R.S.; Gajbhiye, K.R.; Ganesh, N. Enhanced Oral Bioavailability of Griseofulvin via Niosomes. American Association of Pharmaceutical Scientists 2009, 10, 1186–1192. [Google Scholar] [CrossRef]
  12. Penhasi, A.; Reuveni, A.; Shoshani, E. Local Therapeutic Release device. United States Patent 0100192 A1, 2012. [Google Scholar]
  13. Singh, A.; et al. Development and Characterization of Moxifloxacin HCl Loaded Dental Strips for Treatment of Periodontitis. Journal of Pharmacy Research 2010, 3, 2836–2839. [Google Scholar]
  14. Belsen David, J.; Manavalan, R.; Parthasarathy, V. Effective Antimicrobial Therapy of Periodontitis- An Overview of Dental/Periodontal Chip. International Journal of Pharmaceutical Development & Technology 2011, 1, 11–19. [Google Scholar]
  15. Reddy, S.H.K.; Reddy, S.A. Periodontal treatment by local drug delivery using resorbable base materials; in-vitro comparative study assessing drug delivery properties of cellulose acetate and alginate strips. Indian Journal of Dental Advancements 2012, 4, 744–749. [Google Scholar]
  16. Bhardwaj, V.; Shukla, V.; Goyal, N.; Malviya, R.; Sharma, P.K. Formulation and Evaluation of Different Concentration Chitosan based Periodontal Film of Ofloxacin. Journal of Pharmacy Research 2010, 3, 528–532. [Google Scholar]
  17. Reddy, N.R.; Ravindra, S.; Kumar, T.P. In-vitro release of tinidazole from polyvinyl alcohol and polyvinylpyrrolidine strips- local drug delivery system to treat periodontal pockets. International Journal of Dental Clinics 2011, 3, 26–28. [Google Scholar]
  18. Kumar, M.; Prabhushankar, G.; Sathesh Babu, P. Formulation and In-vitro Evaluation of Periodontal Films Containing Metronidazole. International Journal of Pharm Tech Research 2010, 2, 2188–2193. [Google Scholar]
  19. Sudeep, K.; et al. Formulation and In-vitro Evaluation of Clarithromycin Periodontal Strips for Periodontitis. International Research Journal of Pharmacy 2012, 3, 265–267. [Google Scholar]
  20. Prabhushankar, G.L.; Gopalkrishna, B.; Manjunatha, K.M.; Girisha, C.H. Formulation and Evaluation of Levofloxacin Dental Films for Periodontitis. International Journal of Pharmacy and Pharmaceutical Sciences 2010, 2, 162–168. [Google Scholar]
  21. Perugini, P.; Genta, I.; Conti, B.; Modena, T.; Pavanetto, F. Periodontal delivery of ipriflavone: New chitosan/PLGA film delivery system for a lipophilic drug. Int. J. Pharm. 2003, 252, 1–9. [Google Scholar] [CrossRef]
  22. Golomb, G.; Friedman, M.; Soskolne, A.; Stabholz, A.; Sela, M. Sustained Release Device Containing Metronidazole for Periodontal Use. J. Dent. Res. 1984, 63, 1149–1153. [Google Scholar] [CrossRef]
  23. Stasiewicz, M.; Karpiński, T.M. The oral microbiota and its role in carcinogenesis. Semin. Cancer Biol. 2021, 86, 633–642. [Google Scholar] [CrossRef] [PubMed]
  24. Ge, X.; Wei, M.; He, S.; Yuan, W.-E. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics 2019, 11, 55. [Google Scholar] [CrossRef] [PubMed]
  25. Kazi, K.M.; Mandal, A.S.; Biswas, N.; Guha, A.; Chatterjee, S.; Behera, M.; Kuotsu, K. Niosome: A future of targeted drug delivery systems. Journal of Advanced Pharmaceutical Technology & Research 2010, 1, 374–380. [Google Scholar]
  26. Saini, P.; Kumar, A.; Sharma, P.; Visht, S. Fast Disintegrating Oral Films: A Recent Trend of Drug Delivery. Int. J. Drug Dev. & Res. 2012, 4, 80–94. [Google Scholar]
  27. Soskolne, W.A. Subgingival Delivery of Therapeutic Agents in the Treatment of Periodontal Diseases. Crit. Rev. Oral Biol. Med. 1997, 8, 164–174. [Google Scholar] [CrossRef] [PubMed]
  28. Chandramouli, M.; Shivalingappa, R.P.; Basavanna, V.; Doddamani, S.; Shanthakumar, D.C.; Nagarajaiah, S.R.; Ningaiah, S. Oral Thin-films from Design to Delivery: A Pharmaceutical Viewpoint. Biointerface Research in Applied Chemistry 2022, 13, 2023. [Google Scholar]
  29. Almangour, T.A.; Kaye, K.S.; Alessa, M.; Eljaaly, K.; Aleanizy, F.S.; Alsharidi, A.; Al Majid, F.M.; Alotaibi, N.H.; Alzeer, A.A.; Alnezary, F.S.; et al. Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials. Saudi Pharm. J. 2021, 29, 315–323. [Google Scholar] [CrossRef]
  30. Keservani, R.K.; Gautam, S.P. Skeletal muscle relaxant activity of different formulation of span 60 niosomes. Ars Pharm. (Internet) 2021, 63, 32–44. [Google Scholar] [CrossRef]
  31. AbuElfadl, A.M.; Boughdady, M.; Meshali, M. New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats. Int. J. Nanomed. 2021, 16, 5581–5601. [Google Scholar] [CrossRef]
  32. Ammar, H.O.; Haider, M.; Ibrahim, M.; El Hoffy, N.M. In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration. Drug Deliv. 2017, 24, 414–421. [Google Scholar] [CrossRef]
  33. Mirzaie, A.; Peirovi, N.; Akbarzadeh, I.; Moghtaderi, M.; Heidari, F.; Yeganeh, F.E.; Noorbazargan, H.; Mirzazadeh, S.; Bakhtiari, R. Preparation and optimization of ciprofloxacin encapsulated niosomes: A new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance Staphylococcus aureus. Bioorg. Chem. 2020, 103, 104231. [Google Scholar] [CrossRef] [PubMed]
  34. Kumar, A.K.S.H.A.Y.; Gupta, V.I.S.H.A.L.; Guda, D.V.; Sivadasu, P.R.A.V.E.E.N. Formulation And Development Of In Situ Forming Gel For The Treatment Of Oral Thrush. Asian J. Pharm. Clin. Res. 2018, 11, 342–346. [Google Scholar] [CrossRef]
  35. Vainionpää, A.; Tuomi, J.; Kantola, S.; Anttonen, V. Neonatal thrush of newborns: Oral candidiasis? Clin. Exp. Dent. Res. 2019, 5, 580–582. [Google Scholar] [CrossRef] [PubMed]
  36. Takakura, N.; Sato, Y.; Ishibashi, H.; Oshima, H.; Uchida, K.; Yamaguchi, H.; Abe, S. A Novel Murine Model of Oral Candidiasis with Local Symptoms Characteristic of Oral Thrush. Microbiol. Immunol. 2003, 47, 321–326. [Google Scholar] [CrossRef] [PubMed]
  37. Ellepola, A.N.; Samaranayake, L.; Khan, Z. Extracellular phospholipase production of oral Candida albicans isolates from smokers, diabetics, asthmatics, denture wearers and healthy individuals following brief exposure to polyene, echinocandin and azole antimycotics. Braz. J. Microbiol. 2016, 47, 911–916. [Google Scholar] [CrossRef] [PubMed]
  38. Awen, B.Z.; Katakam, P.; Rao, C.B.; Mohammed, S.A.; Alokbe, T.O. Design and in-vitro evaluation of controlled release cephalexin subgingival films using natural biodegradable polymer. Recent Research in Science and Technology 2010, 2, 06–11. [Google Scholar]
  39. Nawaz, A.; Jan, S.U.; Khan, N.; Hussain, A.; Khan, G.M. Formulation and in vitro evaluation of clotrimazole gel containing almond oil and tween 80 as penetration enhancer for topical application. Pak J Pharm Science 2013, 26, 617–22. [Google Scholar]
  40. Bash, B.N.; Prakasam, K. Formulation and evaluation of gel containing fluconazole- antifungal agent. Int J Drug Dev Research 2011, 3, 119–27. [Google Scholar]
  41. Balata, G.; Bakera, R.; Mahdi, M. Improvement of solubility and dissolution properties of clotrimazole by solid dispersions and inclusion complexes. Indian J. Pharm. Sci. 2011, 73, 517–26. [Google Scholar] [CrossRef] [PubMed]
  42. Khosravi, A.; Shokri, H.; Darabi, M.; Kashani, A.; Mansouri, P.; Naser, A. Comparative study on the effects of a new antifungal lotion (Artemisia sieberi essential oil) and a clotrimazole lotion in the treatment of pityriasis versicolor. J. Med Mycol. 2009, 19, 17–21. [Google Scholar] [CrossRef]
  43. Sudeep, K.; Gnanaranjan, G.; Preeti, K. Periodontal chip: An adjunct to conventional surgical treatment. Int. J. Drug Res. Tech. 2012, 2, 411–421. [Google Scholar]
  44. Ali, M.S.; Ali, J.; Ahuja, A.; Alam, M.S. Formulation and characterization of Dental Film Containing Ofloxacin. Journal of Applied Pharmaceutical Science 2012, 2, 114–119. [Google Scholar]
  45. Umadevi, S.; Rohini, B.; Nithyapriya, S. Formulation and evaluation of ciprofloxacin dental films for periodontitis. J. Chem. Pharm. Res. 2012, 4, 2964–2971. [Google Scholar]
  46. Şenel, S.; İkinci, G.; Kaş, S.; Yousefi-Rad, A.; Sargon, M.; Hıncal, A. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int. J. Pharm. 2000, 193, 197–203. [Google Scholar] [CrossRef] [PubMed]
  47. Rana, P.; Murthy, R.S.R. Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: A potential approach for delivery of drugs having high first-pass metabolism. Drug Deliv. 2013, 20, 224–235. [Google Scholar] [CrossRef] [PubMed]
  48. Bushetti, S.S.; Mane, P.P.; Kardame, S.S. Development and evaluation of mucoadhesive buccal films of nebivolol. RGUHS J Pharm Science 2011, 1, 157–62. [Google Scholar]
  49. Chaudhary, R.; Qureshi, M.S.; Patel, J.; Panigrahi, U.P.; Giri, I.C. Formulation, development and in-vitro evaluation of mucoadhesive buccal patches of methotrexate. Int J Pharma Sci Res 2010, 1, 357–65. [Google Scholar]
  50. Giovino, C.; Ayensu, I.; Tetteh, J.; Boateng, J.S. Development and characterization of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): A potential approach for buccal delivery of macromolecules. Int J Pharm 2012, 428, 143–51. [Google Scholar] [CrossRef] [PubMed]
  51. Cheng, F.C.; Wang, L.H.; Lin, T.C.; Chang, Y.T.; Lee, M.C.; Chiang, C.P. The impact of integrating oral health education into a microbiology curriculum for students of department of life science. Journal of Dental Sciences, 2022; 17, 1253–1259. [Google Scholar]
  52. Zijnge, V.; Ammann, T.; Thurnheer, T.; Gmür, R. Subgingival biofilm structure. Periodontal Disease 2011, 15, 1–16. [Google Scholar]
  53. Radaic, A.; Kapila, Y.L. The oralome and its dysbiosis: New insights into oral microbiome-host interactions. Computational and Structural Biotechnology Journal 2021, 19, 1335–1360. [Google Scholar] [CrossRef]
  54. Davies, A.N.; Brailsford, S.R.; Beighton, D.; Shorthose, K.; Stevens, V.C. Oral Candidosis in Community-Based Patients with Advanced Cancer. Journal of Pain and Symptom Management 2008, 35, 508–514. [Google Scholar] [CrossRef] [PubMed]
  55. Delaney, C.; O'Donnell, L.E.; Kean, R.; Sherry, L.; Brown, J.L.; Calvert, G.; Nile, C.J.; Cross, L.; Bradshaw, D.J.; Brandt, B.W.; et al. Interkingdom interactions on the denture surface: Implications for oral hygiene. Biofilm 2019, 1, 100002. [Google Scholar] [CrossRef] [PubMed]
  56. Moyes, D.L.; Runglall, M.; Murciano, C.; Shen, C.; Nayar, D.; Thavaraj, S.; Kohli, A.; Islam, A.; Mora-Montes, A.; Challacombe, H.; et al. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of candida albicans in epithelial cells. Cell Host and Microbe 2010, 8, 225–235. [Google Scholar] [CrossRef] [PubMed]
  57. Peña, D.E.R.; Innocentini, L.M.A.R.; Saraiva, M.C.P.; Lourenco, A.G.; Motta, A.C.F. Oral candidiasis prevalence in human immunodeficiency virus-1 and pulmonary tuberculosis coinfection: A systematic review and meta-analysis. Microbial Pathogenesis 2021, 150, 1–6. [Google Scholar] [CrossRef] [PubMed]
  58. de Oliveira Mima, E.G.; Pavarina, A.C.; Dovigo, L.N.; Vergani, C.E.; de Souza Costa, C.A.; Kurachi, C.; Bagnato, V.S. Susceptibility of Candida albicans to photodynamic therapy in a murine model of oral candidosis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2010, 109, 392–401. [Google Scholar] [CrossRef] [PubMed]
  59. Saito, H.; Shodo, R.; Yamazaki, K.; Katsura, K.; Ueki, Y.; Nakano, T.; Oshikane, T.; Yamana, N.; Tanabe, S.; Utsunomiya, S.; et al. The association between oral candidiasis and severity of chemoradiotherapy-induced dysphagia in head and neck cancer patients: A retrospective cohort study. Clinical and Translational Radiation Oncology 2020, 20, 13–18. [Google Scholar] [CrossRef] [PubMed]
  60. Hato, H.; Sakata, K.I.; Sato, J.; Hasebe, A.; Yamazaki, Y.; Kitagawa, Y. Factor associated with oral candidiasis caused by co-infection of Candida albicans and Candida glabrata: A retrospective study. Journal of Dental Sciences 2022, 17, 1458–1461. [Google Scholar] [CrossRef] [PubMed]
  61. He, X.S.; Shi, W.Y. Oral microbiology: Past, present and future. International journal of oral science 2009, 1, 47–58. [Google Scholar] [CrossRef]
  62. Fellows, J.L.; Atchison, K.A.; Chaffin, J.; Chávez, E.M.; Tinanoff, N. Oral Health in America: Implications for dental practice. Journal of the American Dental Association 2022, 153, 601–609. [Google Scholar] [CrossRef]
  63. das Chagas, M.S.; Portela, M.B.; Cerqueira, D.F.; de Souza, I.P.R.; Soares, R.M.; Castro, G.F. Reduction of Candida species colonization in the oral cavity of children infected with human immunodeficiency virus after dental treatment. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2009, 108, 383–388. [Google Scholar] [CrossRef]
  64. AAbullais, S.S.; Perla, N.; Shamsudeen, S.M.; AlShahrani, M.Y.; Ahmad, I.; Baba, S.M.; Khateeb, S.U.; AlQahtani, N.A. Association of oral candidal carriage, candidal density and CD4 count among normal, HIV patients with HAART and without HAART. Journal of King Saud University – Science 2022, 34, 102010. [Google Scholar] [CrossRef]
  65. Zheng, Y.; Li, Z.; He, X. Influence of fixed orthodontic appliances on the change in oral Candida strains among adolescents. Journal of Dental Sciences 2016, 11, 17–22. [Google Scholar] [CrossRef]
  66. Ahmed, M.G.; et al. Preparation and Evaluation of Periodontal Strips of Gatifloxacin for Periodontal Diseases. International Journal of Pharma and Bio Sciences 2010, 1, 1. [Google Scholar]
  67. Addy, M.; Hassan, H.; Moran, J.; Wade, W.; Newcombe, R. Use of Antimicrobial Containing Acrylic Strips in the Treatment of Chronic Periodontal Disease. J. Periodontol. 1988, 59, 557–564. [Google Scholar] [CrossRef]
  68. Hu, C.; Rhodes, D.G. Proniosomes: A Novel Drug Carrier Preparation. International Journal of Pharmaceutics 1999, 185, 23–35. [Google Scholar] [CrossRef] [PubMed]
  69. Verma, S.; Singh, S.K.; Syan, N.; Mathur, P.; Valecha, V. Nanoparticle vesicular systems: A versatile tool for drug delivery. Journal of Chemical and Pharmaceutical Research 2010, 2, 496–509. [Google Scholar]
  70. Mujoriya, R.Z.; Dhamande, K.; Bodla, R.B. Niosomal Drug Delivery System- A Review. International Journal of Applied Pharmaceutics 2011, 3, 7–10. [Google Scholar]
  71. Chavda, Y.; et al. Niosome and Proniosome-Vesicular Structured Dosage Form for Targeted Drug Delivery System. Journal of Advanced Pharmaceutical Research 2011, 2, 175–184. [Google Scholar]
  72. Abhinav, K.; Lal, P.J.; Amit, J.; Vishwabhan, S. Review on Niosomes as Novel Drug Delivery System. International Research Journal of Pharmacy 2011, 2, 61–65. [Google Scholar]
  73. Sankhyan, A.; Pawar, P. Recent Trends in Niosome as Vesicular Drug Delivery System. Journal of Applied Pharmaceutical Science 2012, 2, 20–32. [Google Scholar]
  74. Pawar, S.D.; Pawar, R.G.; Kodag, P.P.; Waghmare, A.S. Niosome: A unique drug delivery system. International Journal of Biology, Pharmacy and Allied Sciences 2012, 1, 406–416. [Google Scholar]
  75. Udasi, T.A.; Wankhade, V.P.; Ingle, L.M.; Atram, S.; Tapar, K.K. Proniosome: A Novel Approach to Vesicular Drug Delivery System. International Journal of Pharmacy and Pharmaceutical Science Research 2012, 3, 1–6. [Google Scholar]
  76. Sharma, R.; Mahatma, R.; Bharkatiya, M.; Goyal, A. Niosomes- as potential drug delivery system. International Journal of Drug Research and Technology 2012, 2, 422–429. [Google Scholar]
  77. Diljyot, K. Niosomes: A new approach to targeted drug delivery. International Journal of Pharmaceutical and Phytopharmacological Research 2012, 2, 53–59. [Google Scholar]
  78. Nagaraju, R.; Udupa, N.; Mathew, J.; Varma, B.R.R. Biodegradable Dental Implants of Ciprofloxacin β-cyclodextrin inculsion complex in treatment of periodontitis. Indian Journal of Experimental Biology 1998, 37, 305–307. [Google Scholar]
  79. Lee, J.Y.; Seo, M.H.; Choi, I.J.; Kim, J.H.; Pai, C.M. Locally Administrable, Biodegradable and Sustained Release Pharmaceutical Composition for Periodontitis and Process for Preparation Thereof. United. United States Patent 6, 193, 994 B1, 2001. [Google Scholar]
  80. Rahman, S.; Ahuja, A.; Ali, J.; Khar, R.K. Site-Specific Delivery Systems for the treatment of Periodontitis. Indian Journal of Pharmaceutical Sciences 2002, 65, 106–112. [Google Scholar]
Preprints 103499 g001
Figure 1. (A) Contour plot showing the impact of factors on the response (B) Three-dimensional response surface plot indicating the impact of factors on the response.
Figure 1. (A) Contour plot showing the impact of factors on the response (B) Three-dimensional response surface plot indicating the impact of factors on the response.
Preprints 103499 g001
Preprints 103499 g002
Figure 2. Morphology of Drug in 500x magnification.
Figure 2. Morphology of Drug in 500x magnification.
Preprints 103499 g002
Preprints 103499 g003
Figure 3. UV Spectra of clotrimazole in Methanol.
Figure 3. UV Spectra of clotrimazole in Methanol.
Preprints 103499 g003
Preprints 103499 g004
Figure 4. UV Spectra of clotrimazole in phosphate buffer pH 6.8.
Figure 4. UV Spectra of clotrimazole in phosphate buffer pH 6.8.
Preprints 103499 g004
Preprints 103499 g005
Figure 5. Calibration curve of clotrimazole in methanol.
Figure 5. Calibration curve of clotrimazole in methanol.
Preprints 103499 g005
Preprints 103499 g006
Figure 6. Calibration curve of clotrimazole in phosphate buffer pH 6.8.
Figure 6. Calibration curve of clotrimazole in phosphate buffer pH 6.8.
Preprints 103499 g006
Preprints 103499 g007
Figure 7. FTIR Spectra of clotrimazole.
Figure 7. FTIR Spectra of clotrimazole.
Preprints 103499 g007
Preprints 103499 g008
Figure 8. FTIR Spectra of physical mixture of drug and excipients.
Figure 8. FTIR Spectra of physical mixture of drug and excipients.
Preprints 103499 g008
Preprints 103499 g009
Figure 9. Thermogram of (A) Clotrimazole (B) Formulation.
Figure 9. Thermogram of (A) Clotrimazole (B) Formulation.
Preprints 103499 g009
Preprints 103499 g010
Figure 10. Graphical representation of (A) Particle size (B) Zeta Potential.
Figure 10. Graphical representation of (A) Particle size (B) Zeta Potential.
Preprints 103499 g010
Preprints 103499 g011
Figure 11. TEM images of prepared niosomes.
Figure 11. TEM images of prepared niosomes.
Preprints 103499 g011
Preprints 103499 g012
Figure 12. Images depicting anti-fungal activity.
Figure 12. Images depicting anti-fungal activity.
Preprints 103499 g012
Preprints 103499 g013
Figure 13. In-vitro diffusion study of (A) Clotrimazole loaded film (B) Clotrimazole loaded niosomal film.
Figure 13. In-vitro diffusion study of (A) Clotrimazole loaded film (B) Clotrimazole loaded niosomal film.
Preprints 103499 g013
Preprints 103499 g014
Figure 14. Kinetic Models for Clotrimazole Loaded Film.
Figure 14. Kinetic Models for Clotrimazole Loaded Film.
Preprints 103499 g014
Preprints 103499 g015
Figure 15. Kinetic Models for Clotrimazole Loaded Niosomal Film.
Figure 15. Kinetic Models for Clotrimazole Loaded Niosomal Film.
Preprints 103499 g015
Preprints 103499 g016aPreprints 103499 g016b
Figure 16. Stability Studies.
Figure 16. Stability Studies.
Preprints 103499 g016aPreprints 103499 g016b
Table 1. Different levels for variables in the Plackett Burman Factorial Design.
Table 1. Different levels for variables in the Plackett Burman Factorial Design.
Factors Lower Level
(-)		 Higher Level
(+)
A) Speed of rotation 80 130
B) Cholesterol: Surfactant ratio 1:2 1:3
C) Hydration Time 30 mins 60 mins
D) Temperature 40ᵒC 45ᵒC
E) Amount of hydration solvent 10 ml 20 ml
F) Dummy - +
G) Dummy - +
Table 2. Design of experiment using Plackett Burman Factorial Design for optimization of niosome.
Table 2. Design of experiment using Plackett Burman Factorial Design for optimization of niosome.
Run Speed of Rotation (rpm) Cholesterol: Surfactant ratio Hydration Time (mins) Temperature (ᵒC) Amount of Hydration Solvent (ml) Dummy Dummy Entrapment Efficiency (%)
1 130 1:1:2 30 45 10 + + 85.14
2 130 1:1:3 30 40 20 - + 69.92
3 130 1:1:3 60 40 10 + - 78.40
4 80 1:1:3 60 45 10 - + 88.46
5 130 1:1:2 60 45 20 - - 83.64
6 80 1:1:3 30 45 20 + - 85.00
7 80 1:1:2 60 40 20 + + 81.64
8 80 1:1:2 30 40 10 - - 84.88
Table 3. Design of experiment using 23 Factorial Design for optimization of niosomes.
Table 3. Design of experiment using 23 Factorial Design for optimization of niosomes.
Run Speed of Rotation (rpm) Temperature (ᵒC) Amount of Hydration Solvent (ml) Entrapment Efficiency (%)
1 80 40 10 84.32
2 130 40 10 78.10
3 80 45 10 77.80
4 130 45 10 78.94
5 80 40 20 71.12
6 130 40 20 79.52
7 80 45 20 77.46
8 130 45 20 67.36
Table 4. ANOVA Statistical Analysis.
Table 4. ANOVA Statistical Analysis.
Source F-value p-value
Model 53.57 0.0184 significant
A- Speed of rotation 8.03 0.1052
B- Temperature 23.11 0.0406
C- Amount of Hydration Solvent 98.16 0.0100
AB 21.69 0.0431
ABC 116.87 0.0084
Table 5. Results of regression analysis for response.
Table 5. Results of regression analysis for response.
Responses R2 Adjusted R2 Predicted R2 Adeq Precision
Entrapment Efficiency (%) 0.9926 0.9741 0.8814 23.1561
Table 6. The optimized response predicted by design of experiments and the experimental data for the response under the optimum conditions, n = 3.
Table 6. The optimized response predicted by design of experiments and the experimental data for the response under the optimum conditions, n = 3.
Response Predicted by DOE Experimental Data
Entrapment Efficiency (%) 75.85 74.66 ± 3.12
Table 7. Peaks of FTIR Spectra of drug and physical mixture of drug and excipients.
Table 7. Peaks of FTIR Spectra of drug and physical mixture of drug and excipients.
Expected Peak Range (cm-1) Observed Peak Range of drug (cm-1) Observed Peak Range of physical mixture (cm-1) Functional Group
3100-3000 3063.99 3063.99 =C-H stretch
1600-1400 1433.66 1466.44 Aromatic C=C stretch
1350-1200 1305.40 1276.90 C-N stretch
860-680 765.28 752.46 Aromatic C-H bending
1700-1500 1566.20 1566.20 Aromatic C=C bending
800-600 708.28 695.45 C-Cl stretch
Table 8. Regression Coefficient value obtained from kinetic release models.
Table 8. Regression Coefficient value obtained from kinetic release models.
Release Model Equation Clotrimazole Film (R2) Niosomal Film (R2)
Zero-order Ct = C0 + K0t 0.876 0.961
First-order log C = log C0 + Kt/2.303 0.885 0.957
Korsmeyer-Peppas Ktn = Mt/M∞ 0.867 0.900
Higuchi Q = KH√t 0.950 0.785
Hixson- Crowell Kt = C01/3–Ct1/3 0.882 0.959
Table 9. Physico-chemical Properties.
Table 9. Physico-chemical Properties.
Parameters Results
Thickness 0.52 ± 0.03 mm
Drug Content 90.82 ± 0.67 %
Weight Variation 0.64 ± 0.21 gm
Tensile Strength 1.62 ± 0.02 kg⁄cm2
Folding Endurance 250 ± 12 times
Percent Moisture Uptake 20.47 ± 0.66 %
Percent Moisture Content 40.25 ± 7.85 %
Table 10. Stability Studies.
Table 10. Stability Studies.
Parameters (Months) Appearance Drug Content
%		 Entrapment Efficiency
%
5-8 ± 2ᵒC
0 White and Smooth 91.44 79.08
1 White and Smooth 91.40 77.06
2 White and Smooth 90.88 75.60
3 White and Smooth 89.87 72.00
25 ± 2ᵒC
0 White and Smooth 91.44 79.08
1 White and Slightly Shrink 91.25 78.40
2 White and Slightly Shrink 90.00 75.03
3 White and Slightly Shrink 89.02 72.03
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated